Fludarabine, Cyclophosphamide, and Rituximab or Alemtuzumab in Treating CLL2007 CLL 2007 FMP

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

178 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-11-30

Study Completion Date

2013-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

RATIONALE: Drugs used in chemotherapy, such as fludarabine and cyclophosphamide, work in different ways to kill cancer cells or stop them from growing. Monoclonal antibodies, such as rituximab and alemtuzumab, can block cancer growth in different ways. Some find cancer cells and help kill them or carry cancer-killing substances to them. Others interfere with the ability of cancer cells to grow and spread. It is not yet known whether giving fludarabine and cyclophosphamide together with rituximab is more effective than giving fludarabine and cyclophosphamide together with alemtuzumab in treating B-cell chronic lymphocytic leukemia.

PURPOSE: This randomized phase III trial is studying giving fludarabine together with cyclophosphamide and rituximab to see how well it works as first-line therapy compared with giving fludarabine together with cyclophosphamide and alemtuzumab in treating patients with B-cell chronic lymphocytic leukemia.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Combination Chemotherapy With or Without Rituximab in Treating Patients With Previously Treated Chronic Lymphocytic Leukemia

NCT00337246

Leukemia

COMPLETED PHASE2

Fludarabine, Rituximab, and Alemtuzumab in Treating Patients With Chronic Lymphocytic Leukemia

NCT00098670

B-cell Chronic Lymphocytic Leukemia Stage I Chronic Lymphocytic Leukemia Stage II Chronic Lymphocytic Leukemia +2 more

COMPLETED PHASE2

Fludarabine and Alemtuzumab or Cyclophosphamide Followed by Peripheral Blood Stem Cell Transplant or Alemtuzumab in Treating Patients With Advanced or Progressive Chronic Lymphocytic Leukemia

NCT00462332

Leukemia

COMPLETED PHASE2

Fludarabine, Cyclophosphamide, and Rituximab in Treating Patients Who Have Chronic Lymphocytic Leukemia

NCT00003659

Leukemia

COMPLETED PHASE2

Combination Chemotherapy Followed By Alemtuzumab in Treating Patients With Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia

NCT00278213

Prolymphocytic Leukemia

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

OBJECTIVES:

Primary

* To compare 36-month progression-free survival in patients with Binet stage B or C B-cell chronic lymphocytic leukemia treated with first-line therapy comprising fludarabine phosphate and cyclophosphamide and either rituximab or alemtuzumab.

Secondary

* To compare the disease-free survival, event-free survival, and overall survival of patients treated with these regimens.
* To compare time to next treatment in patients treated with these regimens.
* To compare the overall response rate (complete response \[CR\] and partial response \[PR\]) in patients treated with these regimens.
* To compare the rate of phenotypic and molecular response in patients treated with these regimens.
* To compare the duration of phenotypic, molecular, complete and partial responses in patients treated with these regimens.
* To compare the response rates and survival times in biological subgroups.
* To compare the rates of treatment-related adverse effects in patients treated with these regimens.
* To compare the quality of life of patients treated with these regimens.
* Minimal residual disease study.

OUTLINE: This is a multicenter study. Patients are stratified according to Ig mutational status and cytogenetic abnormalities. Patients are randomized to 1 of 2 treatment arms.

* Arm I: Patients receive rituximab IV on day 1 and fludarabine phosphate and cyclophosphamide IV or orally on days 2-4 of course 1. Beginning in course 2 and for all subsequent courses, patients receive rituximab IV on day 1 and fludarabine phosphate and cyclophosphamide IV or orally on days 1-3.
* Arm II: Patients receive alemtuzumab subcutaneously, oral fludarabine phosphate, and oral cyclophosphamide on days 1-3.

In both arms, treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed every 6 months.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Leukemia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

FCCAM

Fludarabine-Cyclophosphamide-Campath (FCCam) Oral Fludarabine: 40 mg/m2 per os, D1 to D3 Oral Cyclophosphamide: 250 mg/m2/day as one dose at noon, D1 to D3 Campath®: 30 mg sc, D1 to D3 without dose escalation

Group Type EXPERIMENTAL

rituximab

Intervention Type BIOLOGICAL

Fludarabine-Cyclophosphamide-Rituximab (FCR)

cyclophosphamide

Intervention Type DRUG

Fludarabine-Cyclophosphamide-Campath (FCCAM) Fludarabine-Cyclophosphamide-Rituximab (FCR)

fludarabine

Intervention Type DRUG

Fludarabine-Cyclophosphamide-Campath (FCCAM) Fludarabine-Cyclophosphamide-Rituximab (FCR)

FCR

Fludarabine-Cyclophosphamide-Rituximab (FCR)

First course:

Rituximab 375 mg/m2 on D1.

D2 to D4:

oral Fludarabine: 40 mg/m2/day as a single morning dose oral Cyclophosphamide: 250 mg/m2/day as a single dose at noon

Subsequent courses (2 to 6)

Rituximab 500 mg/m2 on D1

D1 to D3:

oral Fludarabine: 40 mg/m2/day as a single morning dose oral Cyclophosphamide: 250 mg/m2/day as a single dose at noon

Group Type ACTIVE_COMPARATOR

Campath

Intervention Type BIOLOGICAL

Fludarabine-Cyclophosphamide-Campath (FCCam)

cyclophosphamide

Intervention Type DRUG

Fludarabine-Cyclophosphamide-Campath (FCCAM) Fludarabine-Cyclophosphamide-Rituximab (FCR)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Campath

Fludarabine-Cyclophosphamide-Campath (FCCam)

Intervention Type BIOLOGICAL

rituximab

Fludarabine-Cyclophosphamide-Rituximab (FCR)

Intervention Type BIOLOGICAL

cyclophosphamide

Fludarabine-Cyclophosphamide-Campath (FCCAM) Fludarabine-Cyclophosphamide-Rituximab (FCR)

Intervention Type DRUG

fludarabine

Fludarabine-Cyclophosphamide-Campath (FCCAM) Fludarabine-Cyclophosphamide-Rituximab (FCR)

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Alemtuzumab Mabthera® Endoxan® Fludara®

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Diagnosis of B-cell chronic lymphocytic leukemia (CLL), meeting the following criteria:

* Binet classification stages B or C
* Del 17 p (FISH) negative (\< 10 % positives cores)
* Matutes score 4 or 5

Exclusion Transformation to aggressive B-cell malignancy (e.g. diffuse large cell lymphoma, Hodgkin lymphoma, or prolymphocytic leukemia)

PATIENT CHARACTERISTICS:

Exclusion ECOG performance status ≥ 2

* Life expectancy \< 6 months
* Creatinine clearance \< 60 mL/min
* Total bilirubin \> 2 x upper limit of normal (ULN)
* Gamma glutamyltransferase or transaminase levels \> 2 x ULN
* Cumulative illness rating scale \> 6
* HIV seropositivity
* Hepatitis B or C seropositivity (unless clearly due to vaccination)
* Clinically significant autoimmune anemia
* Active bacterial, viral, or fungal infection
* Active second malignancy currently requiring treatment (except basal cell carcinoma or in situ endometrial carcinoma) and/or less than 5 years complete remission after breast cancer
* Any severe comorbid conditions including, but not limited to, any of the following:

* Class III or IV heart failure
* Recent myocardial infarction
* Unstable angina
* Ventricular tachyarrhythmias requiring ongoing treatment
* Severe chronic obstructive pulmonary disease with hypoxemia
* Uncontrolled diabetes mellitus
* Uncontrolled hypertension
* Concomitant disease requiring prolonged use of corticosteroids (\> 1 month)
* Known hypersensitivity with anaphylactic reaction to humanized monoclonal antibodies or any of the study drugs
* Contraindication to the use of rituximab or alemtuzumab according to Summary of Product Characteristics
* Any coexisting medical or psychological condition that would preclude participation in the required study procedures
* Any mental deficiency preventing proper understanding of the requirements of treatment
* Person under law control
* Pregnant or breastfeeding women
* Fertile patients who cannot or do not wish to use an effective method of contraception, during and for 12 months after the final treatment used for the purposes of the study

PRIOR CONCURRENT THERAPY:

Inclusion

* No prior chemotherapy, radiotherapy, or immunotherapy for CLL
* Corticosteroids within the past month allowed

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No